Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.

Joussen AM, Wolf S, Kaiser PK, Boyer D, Schmelter T, Sandbrink R, Zeitz O, Deeg G, Richter A, Zimmermann T, Hoechel J, Buetehorn U, Schmitt W, Stemper B, Boettger MK.

Br J Clin Pharmacol. 2019 Feb;85(2):347-355. doi: 10.1111/bcp.13794. Epub 2018 Nov 25.

PMID:
30341774
2.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2019 Oct;13(5):1361-1374. doi: 10.1007/s11682-018-9942-9.

PMID:
30155789
3.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

4.

Scheduled versus Pro Re Nata Dosing in the VIEW Trials.

Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R, Goldstein M, Norenberg C, Sandbrink R, Zeitz O.

Ophthalmology. 2015 Dec;122(12):2497-503. doi: 10.1016/j.ophtha.2015.08.014. Epub 2015 Oct 21.

PMID:
26477840
5.

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.

Fitzgerald KC, Munger KL, Köchert K, Arnason BG, Comi G, Cook S, Goodin DS, Filippi M, Hartung HP, Jeffery DR, O'Connor P, Suarez G, Sandbrink R, Kappos L, Pohl C, Ascherio A.

JAMA Neurol. 2015 Dec;72(12):1458-65. doi: 10.1001/jamaneurol.2015.2742.

PMID:
26458124
6.

No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.

Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A.

Neurology. 2015 Nov 10;85(19):1694-701. doi: 10.1212/WNL.0000000000002099. Epub 2015 Oct 9.

7.

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.

Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C.

J Neurol. 2015 Nov;262(11):2466-71. doi: 10.1007/s00415-015-7862-9. Epub 2015 Aug 5.

8.

Reply: To PMID 25068637.

Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group.

Am J Ophthalmol. 2015 Mar;159(3):608. doi: 10.1016/j.ajo.2014.12.016. No abstract available.

PMID:
25681024
9.

Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.

Gonzalez VH, Boyer DS, Schmidt-Erfurth U, Heier JS, Gordon C, Benz MS, Marcus DM, Sabates NR, Vitti R, Kazmi H, Berliner AJ, Soo Y, Zhu X, Moini H, Zeitz O, Sandbrink R, Do DV.

Retina. 2015 Apr;35(4):687-94. doi: 10.1097/IAE.0000000000000430.

PMID:
25621943
10.

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C.

Ann Clin Transl Neurol. 2014 Aug;1(8):605-17. doi: 10.1002/acn3.91. Epub 2014 Aug 22.

11.

Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group.

Am J Ophthalmol. 2014 Nov;158(5):1032-8. doi: 10.1016/j.ajo.2014.07.027. Epub 2014 Jul 25.

PMID:
25068637
12.

Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA.

Ophthalmology. 2014 Jul;121(7):1414-1420.e1. doi: 10.1016/j.ophtha.2014.01.027. Epub 2014 Mar 27. Erratum in: Ophthalmology. 2014 Nov;121(11):2293.

PMID:
24679444
13.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C.

JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993.

14.

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; BENEFIT Study Group.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9. doi: 10.1136/jnnp-2013-306222. Epub 2013 Nov 11.

15.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS.

Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29.

PMID:
24084500
16.

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.

Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group.

Ophthalmology. 2014 Jan;121(1):202-208. doi: 10.1016/j.ophtha.2013.08.012. Epub 2013 Sep 29.

17.

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.

Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, Barkhof F.

Mult Scler. 2014 Feb;20(2):234-42. doi: 10.1177/1352458513494491. Epub 2013 Jul 10.

PMID:
23842212
18.

Interleukin 17F level and interferon β response in patients with multiple sclerosis.

Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C.

JAMA Neurol. 2013 Aug;70(8):1017-21. doi: 10.1001/jamaneurol.2013.192.

19.

Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.

Lampl C, Nagl S, Arnason B, Comi G, O Connor P, Cook S, Jeffery D, Kappos L, Filippi M, Beckmann K, Bogumil T, Pohl C, Sandbrink R, Hartung HP.

J Neurol. 2013 Jul;260(7):1838-45. doi: 10.1007/s00415-013-6888-0. Epub 2013 Mar 17.

PMID:
23504050
20.

VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.

Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R.

Br J Ophthalmol. 2013 Mar;97(3):278-84. doi: 10.1136/bjophthalmol-2012-301504. Epub 2013 Jan 7. Erratum in: Br J Ophthalmol. 2015 Dec;99(12):1746.

PMID:
23298885
21.

Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.

Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA.

Am J Ophthalmol. 2013 Mar;155(3):429-437.e7. doi: 10.1016/j.ajo.2012.09.026. Epub 2012 Dec 4.

PMID:
23218699
22.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
23.

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups.

Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.

PMID:
23084240
24.

Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.

Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, Kappos L, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, Lehr S, Heubach J, Pohl C, Reischl J.

J Neuroinflammation. 2012 Jun 15;9:129. doi: 10.1186/1742-2094-9-129.

25.

Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.

Caloyeras JP, Zhang B, Wang C, Eriksson M, Fredrikson S, Beckmann K, Knappertz V, Pohl C, Hartung HP, Shah D, Miller JD, Sandbrink R, Lanius V, Gondek K, Russell MW.

Clin Ther. 2012 May;34(5):1132-44. doi: 10.1016/j.clinthera.2012.03.004. Epub 2012 Apr 27.

PMID:
22541587
26.

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS; da Vinci Study Group.

Ophthalmology. 2012 Aug;119(8):1658-65. doi: 10.1016/j.ophtha.2012.02.010. Epub 2012 Apr 24.

PMID:
22537617
27.

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.

Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R.

Mult Scler. 2012 Oct;18(10):1466-71. Epub 2012 Apr 4.

28.

Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.

Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA.

Ophthalmology. 2012 May;119(5):1024-32. doi: 10.1016/j.ophtha.2012.01.042. Epub 2012 Mar 21. Erratum in: Ophthalmology. 2012 Nov;119(11):2204.

PMID:
22440275
29.

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.

Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI.

Ann Neurol. 2011 Dec;70(6):897-912. doi: 10.1002/ana.22609. Erratum in: Ann Neurol. 2013 Apr;73(4):561.

30.

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.

Freedman MS, Metzig C, Kappos L, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Yarden J, Spector L, Fire E, Dotan N, Schwenke S, Lanius V, Sandbrink R, Pohl C.

Mult Scler. 2012 Jul;18(7):966-73. doi: 10.1177/1352458511432327. Epub 2011 Dec 19.

31.

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.

Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C; BEYOND Study Group.

Mult Scler. 2012 Feb;18(2):181-95. doi: 10.1177/1352458511418629. Epub 2011 Sep 27.

PMID:
21952094
32.

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Neurology. 2011 Aug 30;77(9):835-43. doi: 10.1212/WNL.0b013e31822c90d7. Epub 2011 Aug 17. Erratum in: Neurology. 2011 Sep 27;77(13):1317.

PMID:
21849647
33.

Evaluation of soluble HLA-G as a biomarker for multiple sclerosis.

Waschbisch A, Sandbrink R, Hartung HP, Kappos L, Schwab S, Pohl C, Wiendl H.

Neurology. 2011 Aug 9;77(6):596-8. doi: 10.1212/WNL.0b013e318228c14d. Epub 2011 Jul 27. No abstract available.

PMID:
21795647
34.

Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.

Acaster S, Swinburn P, Wang C, Stemper B, Beckmann K, Knappertz V, Pohl C, Sandbrink R, Gondek K, Edan G, Kappos L, Freedman M, Hartung HP, Arnason B, Comi G, Filippi M, Jeffery D, O'Connor P, Cook S, Lloyd AJ.

Mult Scler. 2011 Dec;17(12):1504-13. doi: 10.1177/1352458511414039. Epub 2011 Jul 14.

PMID:
21757536
35.

Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial.

Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R; Spheramine Investigational Group.

Lancet Neurol. 2011 Jun;10(6):509-19. doi: 10.1016/S1474-4422(11)70097-7. Epub 2011 May 10.

PMID:
21565557
36.

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.

Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Rückert R, Sandbrink R, Stein D, Yang K, Beckmann K, Heier JS.

Ophthalmology. 2011 Sep;118(9):1819-26. doi: 10.1016/j.ophtha.2011.02.018. Epub 2011 May 5.

PMID:
21546089
37.

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.

Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V.

Neurology. 2011 Apr 5;76(14):1222-8. doi: 10.1212/WNL.0b013e3182143577.

38.

Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis.

van den Elskamp IJ, Knol DL, Vrenken H, Karas G, Meijerman A, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BM, Barkhof F.

Mult Scler. 2010 Jun;16(6):660-9. doi: 10.1177/1352458510364630. Epub 2010 Mar 29.

PMID:
20350960
39.

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.

van den Elskamp IJ, Boden B, Dattola V, Knol DL, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BM, Barkhof F.

Neuroradiology. 2010 Oct;52(10):875-81. doi: 10.1007/s00234-009-0645-1. Epub 2010 Jan 5.

40.

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F.

Arch Neurol. 2009 Nov;66(11):1345-52. doi: 10.1001/archneurol.2009.243.

PMID:
19901165
41.

Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.

De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P; Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study, Havrdova E, Pohl C, Horakova D, Ascherio A, Hafler DA, Karlson EW.

Lancet Neurol. 2009 Dec;8(12):1111-9. doi: 10.1016/S1474-4422(09)70275-3. Epub 2009 Oct 29.

42.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6. Epub 2009 Sep 10.

PMID:
19748319
43.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
44.

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BM.

BMC Neurol. 2009 May 20;9:19. doi: 10.1186/1471-2377-9-19.

45.

Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.

Moraal B, Meier DS, Poppe PA, Geurts JJ, Vrenken H, Jonker WM, Knol DL, van Schijndel RA, Pouwels PJ, Pohl C, Bauer L, Sandbrink R, Guttmann CR, Barkhof F.

Radiology. 2009 Feb;250(2):506-14. doi: 10.1148/radiol.2501080480. Epub 2008 Nov 26.

46.

Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis.

van den Elskamp IJ, Lembcke J, Dattola V, Beckmann K, Pohl C, Hong W, Sandbrink R, Wagner K, Knol DL, Uitdehaag B, Barkhof F.

Mult Scler. 2008 Jul;14(6):764-9. doi: 10.1177/1352458507087842.

PMID:
18611989
47.

Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.

Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, Lampe J, Sandbrink R, Heubach JF, Stürzebecher S, Reischl J.

J Neuroimmunol. 2008 Aug 13;199(1-2):115-25. doi: 10.1016/j.jneuroim.2008.04.036. Epub 2008 Jun 18.

PMID:
18565596
48.

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R; BENEFIT investigators.

J Neurol. 2008 Apr;255(4):480-7. Epub 2007 Nov 15.

PMID:
18004635
49.

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Poppe P, de Vos M, Lasri F, Bauer L, Dahms S, Wagner K, Pohl C, Sandbrink R.

Arch Neurol. 2007 Sep;64(9):1292-8.

PMID:
17846268
50.

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group.

Lancet. 2007 Aug 4;370(9585):389-97.

PMID:
17679016

Supplemental Content

Loading ...
Support Center